As penfluridol could inhibit TNFα-induced NF-κB activity and was effective to alleviate the severity of TNFα and TNFα-stimulated NF-κB activation-driven arthritis, we assessed the treatment efficacy of penfluridol in another TNFα-dominant autoimmune disease, IBD. Here, NFKB1 is linked to inflammatory bowel disease.